Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma

Bookmark and Share
Published: 21 Oct 2018
Views: 3402
Dr Robert J. Motzer - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Robert J. Motzer speaks with ecancer at ESMO 2018 in Munich about results from JAVELIN Renal 101 trial, a randomised phase III study of anti-PD-L1 avelumab and axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma.

Among all patients treated in the experimental arm, mPFS and ORR rates improved, with these results equaling those in the PD-L1 population, with the rate of adverse events was low.

Overall survival data has yet to mature.

For more on this data, watch his presentation of the trial results at a conference session.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.